Sanofi India Ltd Announces 4% Growth in Net Sales & 27% Growth in Operating Profits in Q1-2025

Sanofi India Limited (SIL) has declared its financial results for the quarter ended on March 31st, 2025. The Company has delivered net sales growth of 4% on a comparable basis of continuing business. The successful launch of Soliqua® continues with a steady growth, reinstating confidence and strength in their comprehensive diabetes portfolio. The Company was able to increase its operating profit by 27% vs Q1-2024 due to lower expenses through overall operating efficiencies. The Company is making good progress on its ‘India for India’ strategy through go-to-market initiatives, improving operating efficiency and promoting innovation.